FDA to pilot faster review of generic drugs manufactured in the US
Sets bioequivalence and active pharmaceutical ingredient (API) requirements for its new ANDA prioritisation programme.
List view / Grid view
Sets bioequivalence and active pharmaceutical ingredient (API) requirements for its new ANDA prioritisation programme.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
7 October 2025 | By Rapid Micro Biosystems
This webinar showcases a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
The pharma company’s plan to divest its active pharmaceutical ingredient interests was first announced in 2024.
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
Pharma manufacturing facility construction placed at the heart of a policy announcement made on social media.
As other pharma companies reconsider their investments, Moderna’s focus insulates it from the UK’s drug pricing row.
This whitepaper provides a detailed examination of Lonza’s holistic, data-driven approach to CCI, developed in collaboration with industry experts and applied across our global network for parenteral combination products.
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
Extends its digital transformation partnership with Siemens to make greater use of automation, data and AI in its services.
Bioprocess experts from Sartorius BIA Separations and BridgeBio Gene Therapy illustrate an approach with potential to expedite AAV upstream analytics and lower overall process development costs.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.